Aktienanalyse zu Firefly Neuroscience Inc (AIFF)AIFFFirefly Neuroscience Inc

Firefly Neuroscience, Inc. is an artificial intelligence (AI) company advancing precision neuroscience. The Company's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The Company's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The Company has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset. It operates in the Technology sector.

Firefly Neuroscience Inc is not a good buy right now due to its current price of 1.02, a significantly low RSI of 25.032 indicating oversold conditions, and a troubling 1-year change of -58.02%. The company has shown some revenue growth, with Q2 2026 revenue at 514,000 USD, but continues to post substantial net losses, with a net income of -1,984,000 USD in the same quarter. The primary risk is the high volatility and recent performance, as indicated by a 5-day change of -14.29%.